抗疟药研究进展

doi:10.12140/j.issn.1000-7423.2023.04.015

中国寄生虫学与寄生虫病杂志 ›› 2023, Vol. 41 ›› Issue (4): 486-491.doi: 10.12140/j.issn.1000-7423.2023.04.015

抗疟药研究进展

魏鸾葶¹(), 李润泽², 关良超², 张骞宇³, 李成⁴, 曹雅明⁴, 赵艳⁴^,^*()

1 中国医科大学中英联合学院，辽宁沈阳 110122
2 中国医科大学临床二系，辽宁沈阳 110122
3 中国医科大学临床一系，辽宁沈阳 110122
4 中国医科大学基础医学院免疫学教研室，辽宁沈阳 110122

收稿日期:2023-04-24 修回日期:2023-06-17 出版日期:2023-08-30 发布日期:2023-09-06
通讯作者: *赵艳（1990-），女，博士，副教授，从事抗感染免疫和疟疾分子流行病研究。E-mail：yzhao90@cmu.edu.cn
作者简介:魏鸾葶（2002-），女，本科生，从事免疫学方向研究。E-mail：W3395329716@163.com
基金资助:
国家自然科学基金(82002163)

Research progress of antimalarial drugs

WEI Luanting¹(), LI Runze², GUAN Liangchao², ZHANG Qianyu³, LI Cheng⁴, CAO Yaming⁴, ZHAO Yan⁴^,^*()

1 Queen's University Belfast Joint College, China Medical University, Shenyang 110122, Liaoning, China
2 The Second Clinical Department, China Medical University, Shenyang 110122, Liaoning, China
3 The First Clinical Department, China Medical University, Shenyang 110122, Liaoning, China
4 Department of Immunology, China Medical University, Shenyang 110122, Liaoning, China

Received:2023-04-24 Revised:2023-06-17 Online:2023-08-30 Published:2023-09-06
Contact: *E-mail: yzhao90@cmu.edu.cn
Supported by:
National Natural Science Foundation of China(82002163)

摘要/Abstract

摘要：

疟原虫的耐药性问题是药物治疗疟疾面临的最大挑战。疟原虫对包括青蒿素在内的常见传统抗疟药均产生了不同程度的耐药性，因此，传统药物的改进，以及对新型药物的研发刻不容缓。本文在系统地梳理传统抗疟药的耐药机制、传统药物的改进方法及优化成果和新型抗疟药研究进展的基础上，对疟疾防治策略进行讨论。

关键词: 抗疟药, 耐药性分析, 新药开发, 靶向药物, 防治策略

Abstract:

Antimalarial drug resistance presents the biggest challenge for treatment against malaria. Plasmodium parasites have developed different degrees of resistance to common traditional antimalarial drugs including artemisinin. Therefore, the improvement of traditional drugs and the research and development of new drugs are urgently needed. This paper discusses the malaria control strategies based on a systematic review of the resistance mechanisms against traditional antimalarial drugs, the improvement strategies and optimisation achievements based on traditional drugs, and the research advances of new antimalarial drugs.

Key words: Anti-malarial drugs, Drug resistance analysis, New drug development, Targeted drug, prevention strategy

中图分类号:

R531.3

魏鸾葶, 李润泽, 关良超, 张骞宇, 李成, 曹雅明, 赵艳. 抗疟药研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(4): 486-491.

WEI Luanting, LI Runze, GUAN Liangchao, ZHANG Qianyu, LI Cheng, CAO Yaming, ZHAO Yan. Research progress of antimalarial drugs[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2023, 41(4): 486-491.

图/表 1

表1

传统抗疟药的特征与应用

治疗时期	药物名称	作用机制及优点	耐药机制及不足	应用现状	参考文献
红外期	伯氨喹	干扰疟原虫红外期能量代谢和呼吸作用，对间日疟原虫和卵形疟原虫的子孢子和配子体有杀灭作用，目前尚未发现耐药性。	不良反应明显，可导致红细胞减少，易发生溶血性贫血。	① 治疗耐氯喹的恶性疟原虫 ② 与青蒿素类药物联合使用具有根治作用	[9]
红外期	乙胺嘧啶	抑制二氢酸还原酶抑制细胞的分裂，抑制疟原虫繁殖，具有阻断作用。	二氢叶酸还原酶（Dihydrofolate Reductase，DHFR）S108N的突变导致耐药性产生，使用效果不佳。	① 常用于疟疾的预防与阻断传播 ② 与磺胺多辛联合用于防治耐氯喹的恶性疟	[10-11]
红内期	奎宁	第一种抗疟药，合成方式简单，可抑制有毒的血红素转化为聚合无毒的疟原虫色素，使虫体毒素储积过多死亡。	主要作用靶点为恶性疟原虫嘌呤核苷磷酸化酶的突变，导致耐药性产生，且药效低，不良反应较重。	① 在非洲部分地区治疗重症疟疾方面仍处于核心地位 ② 乌干达等部分非洲地区，治疗耐青蒿素疟原虫	[12-13]
	氯喹	与奎宁作用机制相似，干扰疟原虫繁殖，因具有长半衰期、高效力、低毒性的特点，代替奎宁成为治疗疟疾的首选药物。	氯喹抗性转运蛋白（Plasmodium falciparum chloroquine resistance transporter, Pfcrt）相关基因突变，导致氯喹无法进入疟原虫的消化液泡，无法发挥药效，导致患者病情反复。	① 主要治疗无并发症的恶性疟 ② 与其他药物联合使用	[14-15]
	苯芴醇	形成干扰血红素聚合的复合物，从而阻碍疟原虫裂殖子和配子体的发育，同时血浆半衰期较长，清除疟原虫彻底。	水溶性差，须与高脂肪食物共同服用以增强其在胃肠中的吸收，但这不适用于容易发生食欲不振、恶心、呕吐的疟疾患者；控制症状缓慢，病原虫复燃率高。	① 蒿甲醚-苯芴醇联合用药，增加了治疗疟疾的类型 ② 口服用药，每日仅需服药一次，方便治疗	[16]
	哌喹	作用机制类似于氯喹，半衰期长、消除缓慢，治疗后预防效果持续久。	天冬氨酸蛋白酶2（Plasmepsin2）基因扩增、Pfcrt基因突变等导致耐药性，哌喹单独使用时药效缓慢。	① 双氢青蒿素-哌喹（Dihydroar-temisinin-piperaquine, DHP）联合用药，使疗程缩短、起效加快，可治疗无并发症疟疾 ② 适用范围广，可有效治疗恶性疟和各种混合感染的疟疾	[17⇓⇓-20]
	阿莫地喹	可干扰疟原虫食物液泡中血红素的解毒，从而阻断其在血液阶段的发育，消除较慢。	恶性疟原虫多重抗药性蛋白1 （Plasmodium falciparum multidrug resistance protein 1, Pfmdr1）基因、Pfcrt基因突变导致耐药性，可产生多种不良反应，严重时出现肝损伤。	① 青蒿琥酯-阿莫地喹联合用药，广泛用于治疗单纯性疟疾 ② 清除原发性感染的恶性疟原虫	[21]
	青蒿素及其衍生物	在人体内代谢为二氢青蒿素，携带有过氧基团，被血红素裂解后产生大量氧自由基，使疟原虫营养代谢、免疫防御相关蛋白烷基化，具有安全性高、发挥效应快等优点。	恶性疟原虫Kelch蛋白13（Plasmodium falciparum Kelch protein 13, Pfk13）基因突变导致耐药性，半衰期短，导致患者病情反复。	以青蒿素为基础的联合疗法（atemisinin-based combination therapy，ACT），降低疟原虫产生耐药性的概率	[17⇓⇓⇓⇓-22]

表1

参考文献 63

[1]	World Health Organization. World Malaria Report 2021[R]. Geneva: WHO, 2022.
[2]	Arya A, KojomFoko LP, Chaudhry S, et al. Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: a systematic review of clinical studies from two malaria endemic regions-India and sub-Saharan Africa[J]. Int J Parasitol Drugs Drug Resist, 2021, 15: 43-56.
[3]	Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria[J]. Cochrane Database Syst Rev, 2018, 11(11): CD000363.
[4]	Laurens MB. The promise of a malaria vaccine: are we closer?[J]. Annu Rev Microbiol, 2018, 72: 273-292.
[5]	Mendis K, Rietveld A, Warsame M, et al. From malaria control to eradication: the WHO perspective[J]. Trop Med Int Health, 2009, 14(7): 802-809.
[6]	Brashear AM, Cui LW. Population genomics in neglected malaria parasites[J]. Front Microbiol, 2022, 13: 984394.
[7]	Zamil MF, ArefeenSazed S, HaqueHossainey MR, et al. Anti-malarial investigation of Acoruscalamus, Dichapetalumgelonioides, and Leucasaspera on Plasmodium falciparum strains[J]. J Infect Dev Ctries, 2022, 16(11): 1768-1772.
[8]	Amelo W, Makonnen E. Efforts made to eliminate drug-resistant malaria and its challenges[J]. Biomed Res Int, 2021, 2021: 5539544.
[9]	Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency[J]. Am J Health Syst Pharm, 2018, 75(3): 97-104.
[10]	Dinis DV, Schapira A. Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique[J]. Bull Soc Pathol Exot, 1990, 83(4): 521-528.
[11]	Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future[J]. Ann N Y Acad Sci, 2015, 1342: 62-67.
[12]	Fukuda N, Tachibana SI, Ikeda M, et al. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Northern Uganda[J]. Parasitol Int, 2021, 81: 102277.
[13]	Okombo J, Ohuma E, Picot S, et al. Update on genetic markers of quinine resistance in Plasmodium falciparum[J]. MolBiochem Parasitol, 2011, 177(2): 77-82.
[14]	White NJ. The treatment of malaria[J]. N Engl J Med, 1996, 335(11): 800-806.
[15]	Wellems TE, Plowe CV. Chloroquine-resistant malaria[J]. J Infect Dis, 2001, 184(6): 770-776.
[16]	Mvango S, Matshe WMR, Balogun AO, et al. Nanomedicines for malaria chemotherapy: encapsulation vs. polymer therapeutics[J]. Pharm Res, 2018, 35(12): 237.
[17]	Yang B, Sun YF, Lei Y, et al. Research progress on the treatment of malaria with artemisinin and its derivatives[J]. Chin J Parasitol Parasit Dis, 2021, 39(3): 393-402. (in Chinese)
	(杨博, 孙毅凡, 雷瑶, 等. 青蒿素及其衍生物治疗疟疾的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 393-402.)
[18]	Ashley EA, Phyo AP. Drugs in development for malaria[J]. Drugs, 2018, 78(9): 861-879.
[19]	Abuaku B, Boateng P, Peprah NY, et al. Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana[J]. Front Cell Infect Microbiol, 2022, 12: 1058660.
[20]	Li N, Huang YM, Cai WB, et al. Advances in the study of the sensitivity of Plasmodium falciparum todihydroartemisinin-piperaquine[J]. J Pathog Biol, 2017, 12(10): 1025-1027. (in Chinese)
	(李娜, 黄亚铭, 蔡文斌, 等. 恶性疟原虫对双氢青蒿素-哌喹敏感性研究进展[J]. 中国病原生物学杂志, 2017, 12(10): 1025-1027.)
[21]	Zhao H, Xiang Z, Zhou LC, et al. Research progress of amodiaquine as an antimalarial drug[J]. Chin J Parasitol Parasit Dis, 2022, 40(6): 786-791. (in Chinese)
	(赵卉, 向征, 周隆参, 等. 阿莫地喹作为抗疟药的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(6): 786-791.)
[22]	Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, et al. Artemisinin resistance and malaria elimination: where are we now?[J]. Front Pharmacol, 2022, 13: 876282.
[23]	Urbán P, Fernàndez-Busquets X. Nanomedicine against malaria[J]. Curr Med Chem, 2014, 21(5): 605-629.
[24]	Gujjari L, Kalani H, Pindiprolu SK, et al. Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria[J]. Parasite Epidemiol Control, 2022, 17: e00244.
[25]	Guasch-Girbau A, Fernàndez-Busquets X. Review of the current landscape of the potential of nanotechnology for future malaria diagnosis, treatment, and vaccination strategies[J]. Pharmaceutics, 2021, 13(12): 2189.
[26]	Joshi MC, Egan TJ. Quinoline containing side-chain antimalarial analogs: recent advances and therapeutic application[J]. Curr Top Med Chem, 2020, 20(8): 617-697.
[27]	Faidallah HM, Panda SS, Serrano JC, et al. Synthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates[J]. Bioorg Med Chem, 2016, 24(16): 3527-3539.
[28]	Kalita J, Chetia D, Rudrapal M. Design, synthesis, antimalarial activity and docking study of 7-chloro-4- (2-(substituted benzylidene)hydrazineyl)quinolines[J]. Med Chem, 2020, 16(7): 928-937.
[29]	Guo ZR. Transformation of old drugs: a radical antimalarial drug tafenocil[J]. Acta Pharm Sin, 2022, 57(11): 3446-3450. (in Chinese)
	(郭宗儒. 老药改造: 根治性的抗疟药他非诺奎[J]. 药学学报, 2022, 57(11): 3446-3450.)
[30]	Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria[J]. N Engl J Med, 2019, 380(3): 229-241.
[31]	Zhan YL, Wu YS, Xu FF, et al. A novel dihydroxylated derivative of artemisinin from microbial transformation[J]. Fitoterapia, 2017, 120: 93-97.
[32]	Tafenoquine, LiverTox: clinical and research information on drug-induced liver injury[R]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
[33]	Summers RL, Pasaje CFA, Pisco JP, et al. Chemogenomics identifies acetyl-coenzyme a synthetase as a target for malaria treatment and prevention[J]. Cell Chem Biol, 2022, 29(2): 191-201.e8.
[34]	Knecht W, Loffler M. Inhibition and localization of human and rat dihydroorotate dehydrogenase[J]. Adv Exp Med Biol, 2000, 486: 267-270.
[35]	Hartuti ED, Sakura T, Tagod MSO, et al. Identification of 3, 4-dihydro-2H, 6H-pyrimido[1, 2-c][1, 3]benzothiazin-6-imine derivatives as novel selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase[J]. Int J Mol Sci, 2021, 22(13): 7236.
[36]	Cheng X, Song ZH, Wang X, et al. A network pharmacology study on the molecular mechanism of protocatechualdehyde in the treatment of diabetic cataract[J]. Drug Des Devel Ther, 2021, 15: 4011-4023.
[37]	Li RX, Ling DZ, Tang TK, et al. Discovery of novel Plasmodium falciparum HDAC1 inhibitors with dual-stage antimalarial potency and improved safety based on the clinical anticancer drug candidate quisinostat[J]. J Med Chem, 2021, 64(4): 2254-2271.
[38]	Surur AS, Huluka SA, Mitku ML, et al. Indole: the after next scaffold of antiplasmodial agents?[J]. Drug Des Devel Ther, 2020, 14: 4855-4867.
[39]	Dangi P, Jain R, Mamidala R, et al. Natural product inspired novel indole based chiral scaffold kills human malaria parasites via ionic imbalance mediated cell death[J]. Sci Rep, 2019, 9(1): 17785.
[40]	Chavchich M, van Breda K, Rowcliffe K, et al. The spiroindolone KAE609 does not induce dormant ring stages in Plasmodium falciparum parasites[J]. Antimicrob Agents Chemother, 2016, 60(9): 5167-5174.
[41]	Marin GE, Neag MA, Burlacu CC, et al. The protective effects of nutraceutical components in methotrexate: induced toxicity models-an overview[J]. Microorganisms, 2022, 10(10): 2053.
[42]	White NJ, Pukrittayakamee S, Hien TT, et al. Malaria[J]. Lancet, 2014, 383(9918): 723-735.
[43]	Chughlay MF, El Gaaloul M, Donini C, et al. Chemoprotective antimalarial activity of P218 against Plasmodium falciparum: a randomized, placebo-controlled volunteer infection study[J]. Am J Trop Med Hyg, 2021, 104(4): 1348-1358.
[44]	Mayinger P. Phosphoinositides and vesicular membrane traffic[J]. Biochim Biophys Acta, 2012, 1821(8): 1104-1113.
[45]	McNamara CW, Lee MC, Lim CS, et al. Targeting Plasmodium phosphatidylinositol 4-kinase to eliminate malaria[J]. Nature, 2013, 504(7479): 248-253.
[46]	Paquet T, Le MC, Cabrera DG, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase[J]. Sci Transl Med, 2017, 9(387).
[47]	Kundu M, Dutta A, Roy KK, et al. Identification of 5-(3-(methylsulfonyl)phenyl)-3-(4-(methylsulfonyl)phenyl)-3H-imidazo[4, 5-b]pyridine as novel orally bioavailable and metabolically stable antimalarial compound for further exploration[J]. Chem Biol Drug Des, 2023, 101(3): 690-695.
[48]	Ursing J, Schmidt BA, Lebbad M, et al. Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage?[J]. Infect Genet Evol, 2007, 7(5): 555-561.
[49]	Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria[J]. N Engl J Med, 2014, 371(5): 411-423.
[50]	D'Alessandro U. Progress in the development of piperaquine combinations for the treatment of malaria[J]. Curr Opin Infect Dis, 2009, 22(6): 588-592.
[51]	Kay K, Hodel EM, Hastings IM. Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness[J]. Antimicrob Agents Chemother, 2015, 59(10): 6419-6427.
[52]	Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria[J]. Malar J, 2011, 10: 144.
[53]	Tan KR, Magill AJ, Parise ME, et al. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis[J]. Am J Trop Med Hyg, 2011, 84(4): 517-531.
[54]	Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity[J]. Int J Parasitol, 2002, 32(13): 1655-1660.
[55]	Tanneru N, Nivya MA, Adhikari N, et al. Plasmodium DDI1 is a potential therapeutic target and important chromatin-associated protein[J]. Int J Parasitol, 2023, 53(3): 157-175.
[56]	WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for malaria[R]. Geneva: WHO, 2022.
[57]	Attaher O, Zaidi I, Kwan JL, et al. Effect of seasonal malaria chemoprevention on immune markers of exhaustion and regulation[J]. J Infect Dis, 2020, 221(1): 138-145.
[58]	Aregawi M, Smith SJ, Sillah-Kanu M, et al. Impact of the mass drug administration for malaria in response to the ebola outbreak in Sierra Leone[J]. Malar J, 2016, 15: 480.
[59]	Nikiema S, Soulama I, Sombié S, et al. Seasonal malaria chemoprevention implementation: effect on malaria incidence and immunity in a context of expansion of P. falciparum resistant genotypes with potential reduction of the effectiveness in sub-saharan Africa[J]. Infect Drug Resist, 2022, 15: 4517-4527.
[60]	Ni SJ. The COVID-19 epidemic increases the global burden of malaria[N]. Acta Scientiae Sinica, 2021-12-10( 003). (in Chinese)
	(倪思洁. 新冠肺炎疫情加重全球疟疾负担[N]. 中国科学报, 2021-12-10 (003).)
[61]	Lopes EA, Santos MMM, Mori M. Antimalarial drugs: what's new in the patents?[J]. Expert Opin Ther Pat, 2023, 33(3): 151-168.
[62]	Ambroise-Thomas P. The tragedy caused by fake antimalarial drugs[J]. Mediterr J Hematol Infect Dis, 2012, 4(1): e2012027.
[63]	Phyo AP, Von Seidlein L. Challenges to replace ACT as first-line drug[J]. Malar J, 2017, 16(1): 296.

抗疟药研究进展

Research progress of antimalarial drugs

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 63

相关文章 15

编辑推荐

Metrics

本文评价

[1]	冯家鑫, 公衍峰, 罗卓韦, 汪伟, 曹淳力, 许静, 李石柱. 我国血吸虫病防治策略的科学基础与“十四五”展望[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 428-435.
[2]	李美, 周何军, 尹建海, 张丽, 涂宏. 疟疾患者体内原虫密度与治疗措施调查[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(3): 379-383.
[3]	赵晋英, 刘鹏, 李艳伟, 汪世平. 血吸虫病联合用药的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(3): 370-377.
[4]	郑文琪, 苏秀兰. 抗菌肽的抗疟原虫活性及作用机制的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(6): 643-647.
[5]	高琪. 《抗疟药物使用规范》的解读[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(5): 482-485.
[6]	薛剑1，姜斌1，刘丛珊1，孙军2，肖树华1*. 7种抗疟药抑制疟色素形成及其体外、体内抗日本血吸虫作用的比较观察[J]. 中国寄生虫学与寄生虫病杂志, 2013, 31(3): 1-161-169.
[7]	林丹丹;曾小军;陈红根;洪献林;陶波;李宜锋;熊继杰;周晓农. 鄱阳湖区以传染源控制为主的血吸虫病综合治理策略费用-效果/效益分析[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(4): 2-302.
[8]	陈兆国;AliciaMORENO;AgustinBENITO;MartaMORENO;PedroJ.BERZOSA;AidadeLUCIO;EvaMOYANO. 同位素微量试验法检测新化合物抗恶性疟原虫活性试验[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(1): 20-86.
[9]	黄芳;汤林华;王琴美;倪奕昌. 微量荧光法体外测定恶性疟原虫对4种常用抗疟药的敏感性[J]. 中国寄生虫学与寄生虫病杂志, 2006, 24(1): 10-44.
[10]	刘德全. 疟原虫的抗药性与抗疟药的合理应用[J]. 中国寄生虫学与寄生虫病杂志, 2005, 23(增刊): 8-361.
[11]	黄芳;汤林华. 铁螯合剂类抗疟药的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2005, 23(4): 16-196.
[12]	冯晓平;刘德全. 体外微量法测定恶性疟原虫对抗疟药敏感性的影响因素[J]. 中国寄生虫学与寄生虫病杂志, 2003, 21(4): 12-237.
[13]	王京燕;单成启;符大东;孙志伟;丁德本. 复方萘酚喹及其组分单药治疗恶性疟的临床研究[J]. 中国寄生虫学与寄生虫病杂志, 2003, 21(3): 2-133.
[14]	翟自立;伍卫平. 疟原虫食物泡:抗疟药的靶点[J]. 中国寄生虫学与寄生虫病杂志, 2001, 19(6): 13-366.
[15]	黄建荣;高英起;NganaweiElie. 蒿甲醚伍用伯氨喹治疗恶性疟的研究[J]. 中国寄生虫学与寄生虫病杂志, 2001, 19(5): 15-309.